How Are Medicines Priced in Germany? A Detailed Explanation
Germany’s drug pricing system is strictly regulated by the state, balancing medical innovation, affordability, and protection of the healthcare system from inflation.
Who is responsible for pricing?
Pharmaceutical companies: set the initial launch price.
IQWiG (Institute for Quality and Efficiency in Healthcare): evaluates the “added value” of the new drug compared to existing ones.
G-BA (Federal Joint Committee): decides whether the drug is covered by statutory health insurance and under what conditions.
GKV-Spitzenverband: negotiates the final reimbursable price after one year.
Steps of Pricing
Free initial pricing (first 12 months): Companies set the price freely; insurers cover it fully.
Benefit assessment (Nutzenbewertung): IQWiG and G-BA assess whether the drug offers real added benefit and its effectiveness.
Negotiation of reimbursement price (Erstattungsbetrag): If no significant added benefit, the price is reduced in mandatory negotiations.
Drugs not subject to negotiation
Minor symptom drugs (simple painkillers)
Vitamins
Dietary supplements → usually not covered by insurance, sold freely in pharmacies.
Generic drug pricing
Law obliges insurers to promote cheaper generics.
Festbetrag (fixed amount): maximum reimbursement per drug group.
Patients choosing more expensive drugs pay the difference themselves.
Factors influencing pricing
Medical benefit → higher benefit allows higher initial price
Market size and patient numbers → larger markets push prices down
Comparison with existing drugs → effective alternatives lower the price
Development and production costs → considered in initial pricing
Key German Terms
Erstattungsbetrag = reimbursement price
Festbetrag = fixed maximum price
Nutzenbewertung = benefit assessment
G-BA = Federal Joint Committee
Arzneimittelpreisverordnung = drug pricing regulation
Generika = generics
